Table 3 Meta-analysis between MTHFR C677T polymorphism and ASD risk under genetic models
Genetic Models | Fixed/ Random effect OR(95%CI) | Heterogeneity P | I2(%) | Publication Bias P of Egger’s/Begg test |
|---|---|---|---|---|
Allele Contrast (T vs C) | 1.63 (1.30–2.05)b* | 0.000 | 84.3 | 0.029/0.017 |
Mandatory fortification with folate | ||||
Yes | 1.32 (1.00–1.75)b | 0.000 | 86.2 | 0.441/0.707 |
No | 2.08 (1.40–3.08)b* | 0.000 | 84.4 | 0.044/0.032 |
Population | ||||
Asian | 1.95 (1.14–3.33)b* | 0.000 | 90.3 | 0.178/0.221 |
Caucasian | 1.51 (1.17–1.95)b* | 0.000 | 81.5 | 0.130/0.087 |
Sample source | ||||
Hospital-based | 2.10 (1.34–3.14)b* | 0.000 | 89.6 | 0.062/0.174 |
Population-based | 1.33 (1.11–1.65)b* | 0.006 | 64.3 | 0.267/0.386 |
HWE | ||||
Yes | 1.46 (1.18–1.81)b* | 0.000 | 76.0 | 0.005/0.006 |
No | 2.17 (1.52–3.10)b* | 0.030 | 71.4 | 0.779/1.000 |
Heterozygote (CT vs CC) | 1.66 (1.31–2.11)b* | 0.000 | 69.2 | 0.017/0.008 |
Mandatory fortification with folate | ||||
Yes | 1.45 (1.05–2.00)b* | 0.001 | 76.1 | 0.784/0.707 |
No | 1.95 (1.34–2.82)b* | 0.002 | 66.4 | 0.031/0.020 |
Population | ||||
Asian | 1.80 (1.15–2.80)b* | 0.005 | 72.7 | 0.044/0.221 |
Caucasian | 1.62 (1.20–2.18)b* | 0.000 | 70.4 | 0.098/0.029 |
Sample source | ||||
Hospital-based | 2.23 (1.48–3.35)b* | 0.000 | 76.3 | 0.048/0.108 |
Population-based | 1.26 (1.07–1.48)a* | 0.249 | 22.6 | 0.191/0.266 |
HWE | ||||
Yes | 1.49 (1.18–1.87)b* | 0.005 | 57.9 | 0.007/0.009 |
No | 2.24 (1.40–3.58)b* | 0.064 | 63.6 | 0.001/0.296 |
Homozygote (TT vs CC) | 2.03 (1.33–3.09)b* | 0.000 | 74.6 | 0.048/0.053 |
Mandatory fortification with folate | ||||
Yes | 1.66 (0.94–2.94)b | 0.000 | 84.7 | 0.355/0.700 |
No | 2.78 (1.35–5.73)b* | 0.001 | 66.5 | 0.044/0.074 |
Population | ||||
Asian | 2.45 (0.95–6.31)b | 0.000 | 81.2 | 0.286/0.806 |
Caucasian | 1.92 (1.16–3.16)b* | 0.000 | 73.7 | 0.147/0.119 |
Sample source | ||||
Hospital-based | 2.54 (1.26–5.16)b* | 0.000 | 82.5 | 0.142/0.536 |
Population-based | 1.61 (1.01–2.58)b* | 0.031 | 54.7 | 0.122/0.266 |
HWE | ||||
Yes | 1.50 (1.05–2.13)b* | 0.012 | 53.4 | 0.006/0.012 |
No | 4.72 (3.26–6.84)a* | 0.988 | 0.0 | 0.291/1.000 |
Dominant (TT + CT vs CC) | 1.82 (1.39–2.37)b* | 0.000 | 78.6 | 0.021/0.010 |
Mandatory fortification with folate | ||||
Yes | 1.49 (1.04–2.15)b* | 0.000 | 83.3 | 0.775/0.707 |
No | 2.22 (1.46–3.36)b* | 0.000 | 76.3 | 0.051/0.049 |
Population | ||||
Asian | 2.03 (1.21–3.42)b* | 0.000 | 82.7 | 0.164/0.221 |
Caucasian | 1.73 (1.25–2.41)b* | 0.000 | 78.4 | 0.089/0.029 |
Sample source | ||||
Hospital-based | 2.51 (1.57–4.02)b* | 0.000 | 84.6 | 0.050/0.108 |
Population-based | 1.32 (1.13–1.54)a* | 0.066 | 47.2 | 0.253/0.266 |
HWE | ||||
Yes | 1.59 (1.23–2.04)b* | 0.000 | 68.3 | 0.008/0.003 |
No | 2.59 (1.60–4.18)b* | 0.038 | 69.5 | 0.016/0.296 |
Recessive (TT vs CT + CC) | 1.59 (1.14–2.22)b* | 0.000 | 65.6 | 0.033/0.053 |
Mandatory fortification with folate | ||||
Yes | 1.37 (0.93–2.00)b | 0.003 | 72.3 | 0.114/0.707 |
No | 2.23 (1.13–4.38)b* | 0.002 | 65.1 | 0.039/0.283 |
Population | ||||
Asian | 2.07 (0.84–5.10)b* | 0.000 | 81.5 | 0.243/0.806 |
Caucasian | 1.47 (1.04–2.07)b* | 0.015 | 54.7 | 0.138/0.087 |
Sample source | ||||
Hospital-based | 1.76 (1.02–3.04)b* | 0.000 | 76.0 | 0.155/0.386 |
Population-based | 1.41 (1.11–1.80)a* | 0.057 | 48.9 | 0.122/0.266 |
HWE | ||||
Yes | 1.23 (1.02–1.48)a* | 0.025 | 48.7 | 0.006/0.033 |
No | 2.79 (2.05–3.80)a* | 0.459 | 0.0 | 0.489/1.000 |